Wenqing Yu

APRIL- and BAFF/APRIL-targeted therapies for IgA nephropathy: meta-analysis of placebo-controlled trials

Phase 3 interim reports have expanded the evidence for therapies targeting a proliferation-inducing ligand (APRIL) alone or both B-cell activating factor (BAFF) and APRIL in IgA nephropathy (IgAN). We evaluated their effects relative to placebo on proteinuria, kidney function, ph...